Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7522581 | 0.83 | ALDH1A1 (0.43) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8062705 | 0.81 | ALDH1A1 (0.46) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8062706 | 0.81 | ALDH1A1 (0.46) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8067305 | 0.78 | PRKCZ (0.47) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8067302 | 0.78 | PRKCZ (0.47) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8771212 | 0.78 | KMO (0.49) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1532918 | 0.78 | PRKCZ (0.54) | FFAR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL31560378 | 0.77 | FFAR1 (0.46) | FFAR1ALDH1A1LMNA | |
| SCHEMBL11497773 | 0.76 | FFAR1 (0.48) | FFAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7025675 | 0.76 | IDO1 (0.38) | ALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-0934271-B1 | SUBSTITUTED ARYLALKYLAMINES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| EP-0848706-B1 | SUBSTITUTED BENZENE-FUSED HETEROCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| EP-0823896-B1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0934271-A1 | SUBSTITUTED ARYLALKYLAMINES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5840725-A | Substituted oximes, hydrazones and olefins as neurokinin antagonists | SCHERING CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5789422-A | PIPERIDINYL COMPOUNDS, TREATMENT OF ASTHMA, COUGH, MIGRAINE, CROHN*S DISEASE, ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0848706-A1 | SUBSTITUTED BENZENE-FUSED HETERO- AND CARBOCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-06-24 | — | — | EP | disclosed |
| WO-1998018761-A1 | SUBSTITUTED ARYLALKYLAMINES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0823896-A1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| US-5696267-A | ANTIHISTAMINES; ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| US-5691362-A | ANTIHISTAMINES, BRONCHODILATORS, ANTIINFLAMMATORY AGENTS, GASTROINTESTINAL DISORDERS | SCHERING-PLOUGH CORPORATION (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996039383-A1 | SUBSTITUTED BENZENE-FUSED HETERO- AND CARBOCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996034857-A1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | FFAR1 664/4885ALDH1A1 760/4885LMNA 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.